BHCM
CTMX icon

Brevan Howard Capital Management’s CytomX Therapeutics CTMX Stock Holding History

Brevan Howard Capital Management’s Portfolio CTMX Stock Details CTMX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.27M Buy
269,202
+257,798
+2,261% +$1.31M 0.01% 782
2025
Q4 		$48.6K Buy
+11,404
New +$43.3K ﹤0.01% 1700
2024
Q2 		– Sell
-18,056
Closed -$39.4K – 1115
2024
Q1 		$39.4K Buy
+18,056
New +$33.3K ﹤0.01% 947

Other funds holding CTMX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Brevan Howard Capital Management's CTMX Position: Q1 2026 in Review

Brevan Howard Capital Management increased its CytomX Therapeutics (CTMX) stake by 2,261% in Q1 2026, buying an estimated $1.31M and bringing the position to 269,202 shares worth $1.27M. The position accounts for 0.01% of the portfolio, ranked #782.

Brevan Howard Capital Management first reported a position in CTMX in Q1 2024 and has held it in 3 quarters since. 179 funds tracked by Wall St. Rank hold CTMX as of Q1 2026.

  • Brevan Howard Capital Management held 269,202 shares of CytomX Therapeutics worth $1.27M as of Q1 2026.
  • Brevan Howard Capital Management bought 257,798 CytomX Therapeutics shares in Q1 2026, an estimated $1.31M.
  • CytomX Therapeutics made up 0.01% of Brevan Howard Capital Management's portfolio in Q1 2026, its #782 holding.
  • Brevan Howard Capital Management first reported a position in CytomX Therapeutics in Q1 2024 and has held it in 3 quarters since.
  • 179 funds tracked by Wall St. Rank held CytomX Therapeutics as of Q1 2026.

Based on Brevan Howard Capital Management's 13F filing for Q1 2026, filed 15 May 2026.